Peptide Array Differential Diagnosis of Autoimmune Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing autoimmune diseases, such as scleroderma and dermatomyositis, face challenges in accurately differentiating between these conditions and other autoimmune diseases due to their similar clinical manifestations, leading to delayed or incorrect diagnoses.
Innovation Solution
A method involving a peptide array with at least 10,000 different peptides synthesized in situ, where a sample from a subject is contacted and the binding of antibodies is detected to obtain a combination of binding signals, which are then compared to reference binding signals from subjects with different autoimmune diseases or healthy individuals, enabling differential diagnosis with an area under the receiver operator characteristic (ROC) curve greater than 0.6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used to diagnose autoimmune diseases, then the diagnostic process is simple and quick, but the diagnostic accuracy is low due to similar clinical manifestations between different autoimmune diseases
Solution Approach 1:
The diagnostic approach segments the autoimmune disease classification problem by identifying and analyzing specific subsets of autoantibodies that are characteristic of different disease types. Instead of treating all autoantibody testing as a single process, the method divides the analysis into disease-specific patterns, allowing for more precise differentiation between conditions like scleroderma and dermatomyositis while maintaining a manageable diagnostic workflow
Solution Approach 2:
The invention transitions from traditional single-dimension diagnostic criteria (clinical symptoms alone) to a multi-dimensional approach that incorporates autoantibody binding patterns across multiple peptides. This dimensional expansion allows differentiation of diseases that appear similar clinically by adding the immunological profile dimension, thereby improving diagnostic accuracy without excessive complexity
2Measurement precision
If a large number of peptides are tested to improve differential diagnosis accuracy, then the diagnostic precision increases, but the time and resources required for testing increase
Solution Approach 1:
The method performs preliminary identification of disease-specific autoantibody patterns by comparing patient profiles against reference profiles from subjects with known diagnoses. This preliminary action allows the system to quickly identify characteristic binding patterns associated with specific autoimmune diseases, reducing the need for exhaustive testing of all possible peptide-antibody combinations and thereby reducing testing time while maintaining high accuracy
Solution Approach 2:
The invention optimizes the testing parameters by selecting specific peptides that are most discriminative for different autoimmune diseases. Rather than uniformly testing all peptides, the method adjusts the parameters of peptide selection based on their diagnostic utility, focusing resources on the most informative tests and reducing overall testing time while preserving diagnostic precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate differential diagnosis of autoimmune diseases by distinguishing between scleroderma, dermatomyositis, and other autoimmune conditions, improving diagnostic accuracy and identifying disease progression, with a high ROC curve indicating effective differentiation.
Implementation Method 1
detecting the binding of antibodies present in said sample to at least 25 peptides on said array to obtain a combination of binding signals
Data Source
AI summary
Provided herein are methods, assays and devices for the differential diagnosis and detection of disease progression of autoimmune diseases. The methods, assays and devices provided herein produce and analyze binding patterns of peripheral-blood antibodies on mimetic peptide arrays that differentiate autoimmune diseases, and identify patients progressing to internal organ complications such as interstitial lung disease (ILD), and gastric antral vascular ectasia (GAVE), or renal involvement.